Literature DB >> 15094700

Risk factors for liver fibrosis progression in patients with chronic hepatitis C.

Mercedes de Torres1, Thierry Poynard.   

Abstract

The major hepatological consequence of HCV infection is the progression to cirrhosis and its potential complications. Several factors have been clearly shown to be associated with fibrosis progression rate: duration of infection, age, male sex, consumption of alcohol, HIV coinfection and low CD4 count. As age and duration of infection increases, the risk of fibrosis increases and the impact of treatment (IFN) decreases. In conclusion, fibrosis progression has a progressive acceleration, sex, age and consumption of alcohol are strongly involved in this progression; the possibility to assess with non-aggressive biochemical markers the fibrosis stage will probably allow in the future to identify other factors related to fibrosis progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15094700

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  18 in total

1.  Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C.

Authors:  Anneloes E Bohte; Annikki de Niet; Louis Jansen; Shandra Bipat; Aart J Nederveen; Joanne Verheij; Valeska Terpstra; Ralph Sinkus; Karin M J van Nieuwkerk; Rob J de Knegt; Bert C Baak; Peter L M Jansen; Henk W Reesink; Jaap Stoker
Journal:  Eur Radiol       Date:  2013-10-25       Impact factor: 5.315

2.  Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis.

Authors:  Caroline J Sands; Indra N Guha; Michael Kyriakides; Mark Wright; Olaf Beckonert; Elaine Holmes; William M Rosenberg; Muireann Coen
Journal:  Am J Gastroenterol       Date:  2014-12-23       Impact factor: 10.864

Review 3.  HIV and aging: implications for patient management.

Authors:  Kelly A Gebo
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.

Authors:  Veronica Bernabucci; Alessia Ciancio; Salvatore Petta; Aimilia Karampatou; Laura Turco; Silvia Strona; Rosina Critelli; Paola Todesca; Caterina Cerami; Caterina Sagnelli; Mario Rizzetto; Calogero Cammà; Erica Villa
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

5.  Use of biomarkers of collagen types I and III fibrosis metabolism to detect cardiovascular and renal disease in chimpanzees (Pan troglodytes).

Authors:  John J Ely; Micah A Bishop; Michael L Lammey; Meg M Sleeper; Jörg M Steiner; D Rick Lee
Journal:  Comp Med       Date:  2010-04       Impact factor: 0.982

6.  Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.

Authors:  Hirofumi Uto; Joji Kurogi; Yuka Takahama; Kazunori Kusumoto; Katsuhiro Hayashi; Akio Ido; Michinori Kohara; Sherri O Stuver; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

7.  Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals.

Authors:  Kathleen A Brady; Mark Weiner; Barbara J Turner
Journal:  J Infect       Date:  2009-05-03       Impact factor: 6.072

8.  Clinical care of the HIV-infected drug user.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

Review 9.  Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.

Authors:  Omar Ramos-Lopez; Erika Martinez-Lopez; Sonia Roman; Nora A Fierro; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

10.  Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup.

Authors:  Marwa Khairy; Mahassen Abdel-Rahman; Maissa El-Raziky; Wafaa El-Akel; Naglaa Zayed; Hany Khatab; Gamal Esmat
Journal:  Hepat Mon       Date:  2012-11-01       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.